OmniAb (OABI) Income from Continuing Operations (2021 - 2026)
OmniAb (OABI) reported Income from Continuing Operations of 7707000.0 for Q1 2026, up 57.65% year-over-year from 4888558.18 in Q1 2025, and up 45.64% on a QoQ basis from 14179000.0 in Q4 2025.
OmniAb (OABI) has 6 years of Income from Continuing Operations data on file, last reported at 7707000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 57.65% year-over-year to 7707000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 54286000.0 (up 11.4% YoY) and the FY2025 annual result came in at 64779000.0, down 4.43% from the prior year.
- Income from Continuing Operations advanced to 7707000.0 in Q1 2026 per OABI's latest filing, from 14179000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 6820000.0 in Q4 2022 and bottomed at 18961000.0 in Q1 2024.
- The 5-year median for Income from Continuing Operations is 14053000.0 (2023), against an average of 12204235.29.
- Peak annual rise in Income from Continuing Operations reached 119.25% in 2022, while the deepest fall reached 470197.48% in 2022.
- Tracing OABI's Income from Continuing Operations over 5 years: stood at 6820000.0 in 2022, then slumped by 306.06% to 14053000.0 in 2023, then grew by 7.01% to 13068000.0 in 2024, then fell by 8.5% to 14179000.0 in 2025, then soared by 45.64% to 7707000.0 in 2026.
- Per Business Quant, the three latest OABI Income from Continuing Operations figures stand at 7707000.0 (Q1 2026), 14179000.0 (Q4 2025), and 16525000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn | -7.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.71 Mn |
| Dec 31, 2025 | -14.18 Mn |
| Sep 30, 2025 | -16.53 Mn |
| Jun 30, 2025 | -15.88 Mn |
| Mar 31, 2025 | -18.20 Mn |
| Dec 31, 2024 | -13.07 Mn |
| Sep 30, 2024 | -16.37 Mn |
| Jun 30, 2024 | -13.63 Mn |
| Mar 31, 2024 | -18.96 Mn |
| Dec 31, 2023 | -14.05 Mn |
| Sep 30, 2023 | -15.74 Mn |
| Jun 30, 2023 | -14.73 Mn |
| Mar 31, 2023 | -6.10 Mn |
| Dec 31, 2022 | 6.82 Mn |
| Sep 30, 2022 | -12.60 Mn |
| Jun 30, 2022 | -10.28 Mn |
| Mar 31, 2022 | -6.28 Mn |
| Dec 31, 2021 | -35.43 Mn |
| Sep 30, 2021 | -170,579.00 |
| Jun 30, 2021 | -2,185.00 |
| Mar 31, 2021 | -7,786.00 |